Protease inhibitor treats DR

Article

ASP-440 - a protease, developed by ActiveSite Pharmaceuticals and an inhibitor of plase kallikrein - may provide an effective therapeutic treatment for diabetic retinopathy (DR), according to study results published in the February 2009 issue of Hypertension.

ASP-440 - a protease, developed by ActiveSite Pharmaceuticals and an inhibitor of plase kallikrein - may provide an effective therapeutic treatment for diabetic retinopathy (DR), according to study results published in the February 2009 issue of Hypertension.

Edward P. Feener, PhD of Harvard Medical School and the Joslin Diabetes Center, Boston, US and colleagues tested ASP-440 through continuous systemic administration to rodents whose vasculature had been compromised by hypertension.

In the animal model, ASP-440 reduced the permeability of the retinal vasculature by up to 70%, and also reduced elevated blood pressure.

The team concluded that, by reducing retinal permeability through inhibition of kallikrein, ASP-440 may be able to reduce the incidence of diabetic macular oedema and diabetic retinopathy.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.